SG11201810646VA - Abrasion-resistant opioid formulations - Google Patents
Abrasion-resistant opioid formulationsInfo
- Publication number
- SG11201810646VA SG11201810646VA SG11201810646VA SG11201810646VA SG11201810646VA SG 11201810646V A SG11201810646V A SG 11201810646VA SG 11201810646V A SG11201810646V A SG 11201810646VA SG 11201810646V A SG11201810646V A SG 11201810646VA SG 11201810646V A SG11201810646V A SG 11201810646VA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- pct
- dosage forms
- cohesion
- abuse
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Emergency Medicine (AREA)
- Botany (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2016031796 | 2016-05-11 | ||
PCT/US2017/022012 WO2017196445A1 (en) | 2016-05-11 | 2017-03-13 | Abrasion-resistant opioid formulations |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201810646VA true SG11201810646VA (en) | 2019-01-30 |
Family
ID=60267549
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201810646VA SG11201810646VA (en) | 2016-05-11 | 2017-03-13 | Abrasion-resistant opioid formulations |
Country Status (5)
Country | Link |
---|---|
US (1) | US20170326134A1 (zh) |
KR (1) | KR20190028656A (zh) |
CN (1) | CN109982690A (zh) |
SG (1) | SG11201810646VA (zh) |
WO (1) | WO2017196445A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020159901A1 (en) * | 2019-01-31 | 2020-08-06 | Relmada Therapeutics, Inc. | Abrasion-resistant opioid formulations which resist abuse and include a sequestered opioid antagonist |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007054976A2 (en) * | 2005-11-08 | 2007-05-18 | Panacea Biotec Ltd. | Lipid based controlled release pharmaceutical composition |
US10960077B2 (en) * | 2006-05-12 | 2021-03-30 | Intellipharmaceutics Corp. | Abuse and alcohol resistant drug composition |
US20080069891A1 (en) * | 2006-09-15 | 2008-03-20 | Cima Labs, Inc. | Abuse resistant drug formulation |
EP2744572B1 (en) * | 2011-08-18 | 2017-12-13 | BioDelivery Sciences International, Inc. | Abuse-resistant mucoadhesive devices for delivery of buprenorphine |
WO2013119231A1 (en) * | 2012-02-09 | 2013-08-15 | Tris Pharma, Inc. | Abuse resistant opioid drug - ion exchange resin complexes having hybrid coatings |
BR112015022567A2 (pt) * | 2013-03-15 | 2017-07-18 | Mallinckrodt Llc | composições compreendendo um opioide e um ingrediente farmacêutico ativo adicional para início rápido e duração prolongada de analgesia que podem ser administradas sem alimento |
CA2910865C (en) * | 2014-07-15 | 2016-11-29 | Isa Odidi | Compositions and methods for reducing overdose |
-
2017
- 2017-03-13 US US15/456,689 patent/US20170326134A1/en not_active Abandoned
- 2017-03-13 CN CN201780038704.XA patent/CN109982690A/zh active Pending
- 2017-03-13 WO PCT/US2017/022012 patent/WO2017196445A1/en active Application Filing
- 2017-03-13 KR KR1020187035821A patent/KR20190028656A/ko not_active Application Discontinuation
- 2017-03-13 SG SG11201810646VA patent/SG11201810646VA/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2017196445A1 (en) | 2017-11-16 |
CN109982690A (zh) | 2019-07-05 |
KR20190028656A (ko) | 2019-03-19 |
US20170326134A1 (en) | 2017-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201909949XA (en) | Targeted immunotolerance | |
SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
SG11201808990QA (en) | Compositions for topical application of compounds | |
SG11201907427YA (en) | Engineered transferrin receptor binding polypeptides | |
SG11201907023UA (en) | Method of reducing neutropenia | |
SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
SG11201804836RA (en) | Treatment of fibrosis | |
SG11201807279QA (en) | Binding proteins and methods of use thereof | |
SG11201805072PA (en) | Nicotine powder delivery system | |
SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
SG11201907583TA (en) | Methods for treating complement-mediated diseases and disorders | |
SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201810525XA (en) | Anti-gitr antibodies and uses thereof | |
SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
SG11201901438VA (en) | Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate | |
SG11201809534UA (en) | Methods of treating autoimmune disease using allogeneic t cells | |
SG11201808650QA (en) | Methods of treating ocular conditions | |
SG11201810143PA (en) | Exon skipping oligomers for muscular dystrophy | |
SG11201807255YA (en) | Treatment of autoimmune diseases with combinations of rxr agonists and thyroid hormones | |
SG11201805204WA (en) | Nicotine particle capsule | |
SG11201906682YA (en) | Glucagon receptor binding proteins and methods of use thereof | |
SG11201809875VA (en) | Compositions and methods for treating spinal muscular atrophy | |
SG11201809882XA (en) | Pharmaceutical combinations for treating cancer |